Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for John R. Hallal�
125.80
-1.50 (-1.18%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 125.34 - 127.98
52 week 110.56 - 205.29
Open 127.74
Vol / Avg. 0.00/2.39M
Mkt cap 27.85B
P/E 175.24
Div/yield     -
EPS 0.72
Shares 224.02M
Beta 0.89
Inst. own 99%
Jul 28, 2016
Q2 2016 Alexion Pharmaceuticals Inc Earnings Call - 10:00AM EDT - Add to calendar
Jul 28, 2016
Q2 2016 Alexion Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Jun 14, 2016
Alexion Pharmaceuticals Inc at William Blair Growth Stock Conference
Jun 8, 2016
Alexion Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference
Jun 6, 2016
Alexion Pharmaceuticals Inc Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris�) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
May 11, 2016
Alexion Pharmaceuticals Inc Annual Shareholders Meeting
May 10, 2016
Alexion Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2016
Alexion Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Apr 28, 2016
Q1 2016 Alexion Pharmaceuticals Inc Earnings Call
Apr 28, 2016
Q1 2016 Alexion Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 13.15% 5.54%
Operating margin 23.66% 20.61%
EBITD margin - 32.60%
Return on average assets 2.85% 1.67%
Return on average equity 4.53% 2.50%
Employees 2,924 -
CDP Score - -

Address

100 College St
NEW HAVEN, CT 06510-3210
United States - Map
+1-203-2722596 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.

Officers and directors

Leonard Bell M.D. Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
David L. Hallal Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Vikas Sinha CPA Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
John B. Moriarty J.D. Executive Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Saqib Islam J.D. Executive Vice President , Chief Strategy and Portfolio Officer
Age: 46
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 59
Bio & Compensation  - Reuters
Julie O'Neill Executive Vice President - Global Operations
Age: 49
Bio & Compensation  - Reuters
Carsten Thiel Ph.D. Executive Vice President and Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Edward Miller J.D. Senior Vice President, Global Chief Compliance Officer
Age: 51
Bio & Compensation  - Reuters